No Data
SinoMab's SM17 Dermatitis Drug Achieves Endpoints in Phase 1B China Clinical Trial
The validation clinical data of the SM17 Concept exceeded expectations, highlighting the Global growth potential of SINOMAB BIO-B (03681) in the AD field.
SM17 demonstrates differentiated advantages in rapid itching relief, treatment of skin lesions, and safety compared to existing products on the market.
Sinomab Bioscience Narrows 2024 Loss to 185.1 Million Yuan, Revenue Rises to 2.03 Million Yuan
SINOMAB BIO-B (03681.HK) reduced its annual loss to 0.185 billion yuan.
Gelonghui, March 31丨SINOMAB BIO-B (03681.HK) issued an announcement, as of December 31, 2024 and 2023, the company incurred R&D costs of approximately RMB 94.8 million and RMB 135.4 million, respectively. The annual loss decreased by RMB 58 million, from RMB 243.1 million in the previous year to RMB 185.1 million for the current year, mainly due to (i) the acceptance of the BLA for Suciraslimab in September 2023 and starting from November 2023 in China.
Express News | SinoMab BioScience FY Net Income RMB -185.1 Million
SINOMAB BIO-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED 31 DECEMBER 2024; ANDCHANGE IN USE OF PROCEEDS
